In addition to the patient benefit, Mozobil also may offer significant economic benefits for transplant centers. Mozobil has the potential to decrease the number of apheresis days and provide transplant centers with more predictable and efficient use of the apheresis center, while reducing the number of patients who may fail to mobilize sufficient numbers of cells and therefore require a second mobilization procedure.
Additional Therapeutic Opportunities
Numerous Genzyme and investigator-sponsored trials are planned or underway to study Mozobil's use in other settings such as allogeneic hematopoietic stem cell transplants. Genzyme is also studying the use of Mozobil to improve the efficacy of chemotherapy and/or immunotherapy in various types of hematologic malignancies such as chronic lymphocytic leukemia and acute myelogenous leukemia, and is pursuing preclinical work to explore the role that Mozobil may play in cord blood transplantation, solid organ transplantation, cardiovascular disease, renal ischemic disease, and a variety of additional types of solid tumor malignancies.
"We're just beginning to unlock the potential of Mozobil," said Joseph Lobacki, senior vice president of the Transplant business unit at Genzyme.
Mozobil, a novel small molecule CXCR4 chemokine receptor antagonist,
has been shown in multiple earlier studies to rapidly and effectively
increase the number of stem cells in circulation in the blood. Once
circulating in the blood, stem cells can be collected for use in a stem
cell transplant. Mozobil has been granted orp
|SOURCE Genzyme Corporation|
Copyright©2008 PR Newswire.
All rights reserved